Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients

Hepatology

Volumn 21, Issue 2, 1995, Pages 322-327

  Boucher, Eveline ^a   Jouanolle, Herve ^a   Andre, Patrice ^a   Ruffault, Annick ^a   Guyader, Dominique ^a   Moirand, Romain ^a   Turlin, Bruno ^a   Jacquelinet, Christian ^a   Brissot, Pierre ^a   Deugnier, Yves ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON; URSODEOXYCHOLIC ACID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

ADULT; ALANINE TRANSAMINASE; BASE SEQUENCE; BIOPSY; CHRONIC DISEASE; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RNA, VIRAL; URSODEOXYCHOLIC ACID;

EID: 0028960364     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1016/0270-9139(95)90087-X     Document Type: Article

References (46)

1. Hepatitis non-A, non-B at last
2. Blood-born non-A non-B hepatitis hepatitis C
3. Hepatitis C: virology, epidemiology, clinical course, and treatment
4. Importance of the heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis
5. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV)
6. Long term follow-up chronic post transfusion hepatitis
7. Interferon for non-A, non-B chronic hepatitis
8. 2b for 60 weeks
9. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon
10. Comparison of 1 or 3 MU of interferon alpha-2b in patients with chronic non-A, non-B hepatitis
11. Treatment of chronic hepatitis C with recombinant interferon alfa
12. Recombinant interferon alpha therapy for chronic hepatitis C
13. One year treatment of chronic NANB hepatitis with interferon alpha-2b
14. Prolonged treatment (18 months) of chronic hepatitis C with recombinant a-interferon in comparison with a control group
15. Randomized controlled trial of interferon a (lymphoblastoid interferon) in chronic non-A, non-B hepatitis
16. Recombinant human a-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France
17. Is the response to recombinant alpha interferon related to the presence of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis?
18. A randomized controlled trial of interferon a-2b as therapy for chronic non-A, non-B hepatitis
19. A randomized controlled open study of interferon alpha2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies
20. High doses of recombinant α-interferon or α-interferon for chronic hepatitis C: a randomized, controlled trial
21. Long term follow-up of patients with chronic hepatitis C treated with alfa-Interferon
22. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis
23. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis
24. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study
25. Ursodeoxycholic acid in chronic liver disease
26. Treatment of chronic liver disease with ursodeoxycholic acid
27. Effect of different doses of ursodeoxycholic acid in chronic liver disease
28. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis
29. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial
30. Role of cholestasis and bile acids in resistance to recombinant alpha 2 interferon (IFN) therapy in patients with chronic hepatitis C
31. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
32. Sequence analysis of the 5′non coding region of hepatitis C virus
33. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
34. Automated quantitative determination of hepatitis C viremia using reverse transcription-polymerase chain reaction
35. Synthesis of digoxigenin-labelled DNA probe by polymerase chain reaction application to Epstein Barr virus and Chlamydia trachomatis
36. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid
37. Bile acids modulate hepatocyte HLA class I expression in human hepatocytes by a transcriptional mechanism
38. Detection of intrahepatic replication of hepatitis C virus RNA by in situ hybridization and comparison with histopathology
39. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy
40. Hepatic and extrahepatic HCV RNA strands in chronic hepatitis C: different patterns of response to IFN treatment
41. Temporal relationships of hepatitis C virus RNA and antibody responses following experimental infection of chimpanzees
42. Molecular aspects of membrane stabilisation by ursodeoxycholate
43. Influence of hydroxylation and conjugation of bile salts on their membrane damaging properties-studies on isolated hepatocytes and lipid membrane vesicles
44. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts
45. Ursodeoxycholic acid therapy for chronic type C hepatitis-α multicenter dose finding trial
46. Alpha interferon (a IFN) vs a IFN plus ursodeoxycholic acid (UDCA) in chronic hepatitis/C (CH/C) a controlled randomised trial